Cargando…

Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response

SIMPLE SUMMARY: This work establishes that ovarian tumors contain persistent oxidative DNA damage levels that can be measured using Repair Assisted Damage Detection (RADD). The persistent DNA damage correlates with increased protein expression of PD-L1, establishing a link between genomic instabilit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mann, Elise K., Lee, Kevin J., Chen, Dongquan, da Silva, Luciana Madeira, Dal Zotto, Valeria L., Scalici, Jennifer, Gassman, Natalie R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146974/ https://www.ncbi.nlm.nih.gov/pubmed/33946684 http://dx.doi.org/10.3390/biology10050385

Ejemplares similares

Defective base excision repair in the response to DNA damaging agents in triple negative breast cancer
por: Lee, Kevin J., et al.
Publicado: (2019)

Exploiting DNA repair defects in triple negative breast cancer to improve cell killing
por: Lee, Kevin J., et al.
Publicado: (2020)

PD-1/PD-L1 and DNA Damage Response in Cancer
por: Kciuk, Mateusz, et al.
Publicado: (2023)

Perivascular epithelioid cell tumor (PEComa) of the uterus: Challenges of pregnancy in determining prognosis and optimal treatment
por: Wilhite, Annelise M., et al.
Publicado: (2022)

RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance
por: Somasagara, Ranganatha R., et al.
Publicado: (2017)

ALDH1A1 Maintains Ovarian Cancer Stem Cell-Like Properties by Altered Regulation of Cell Cycle Checkpoint and DNA Repair Network Signaling
por: Meng, Erhong, et al.
Publicado: (2014)

407 Glucose activates STAT3, promoting XRCC1 expression and increased DNA repair after exogenous challenge
por: Gassman, Natalie R, et al.
Publicado: (2022)

DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade
por: Xue, Gang, et al.
Publicado: (2019)

Cytoprotective Effect of Vitamin D on Doxorubicin-Induced Cardiac Toxicity in Triple Negative Breast Cancer
por: Lee, Kevin J, et al.
Publicado: (2021)

From single-molecule to genome-wide mapping of DNA lesions: repair-assisted damage detection sequencing
por: Gilat, Noa, et al.
Publicado: (2021)

Bisphenol A Promotes Cell Survival Following Oxidative DNA Damage in Mouse Fibroblasts
por: Gassman, Natalie R., et al.
Publicado: (2015)

PD‐L1 and PD‐L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules
por: Zhang, Yue, et al.
Publicado: (2022)

Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer
por: Xue, Chunyan, et al.
Publicado: (2019)

DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Zhu, Zhongling, et al.
Publicado: (2018)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

Glucose Increases STAT3 Activation, Promoting Sustained XRCC1 Expression and Increasing DNA Repair
por: Wright, Griffin M., et al.
Publicado: (2022)

Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy
por: Ballot, Elise, et al.
Publicado: (2020)

DNA damaging agents in ovarian cancer
por: Barretina-Ginesta, Maria-Pilar
Publicado: (2020)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
por: Dumitru, Adrian, et al.
Publicado: (2022)

ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer
por: Feng, Wenlong, et al.
Publicado: (2020)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
por: Rotman, Jossie, et al.
Publicado: (2020)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
por: Drakes, Maureen L., et al.
Publicado: (2018)

Cutaneous metastasis of PD-L1 positive ovarian carcinoma
por: Hastings, Victoria, et al.
Publicado: (2020)

Platelets Increase the Expression of PD-L1 in Ovarian Cancer
por: Cho, Min Soon, et al.
Publicado: (2022)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
por: Wang, Xueping, et al.
Publicado: (2020)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Alterations of DNA damage response genes correlate with response and overall survival in anti‐PD‐1/PD‐L1‐treated advanced urothelial cancer
por: Joshi, Monika, et al.
Publicado: (2020)

Cell-free DNA in Human Follicular Microenvironment: New Prognostic Biomarker to Predict in vitro Fertilization Outcomes
por: Traver, Sabine, et al.
Publicado: (2015)

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2021)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors
por: Song, Doo-Won, et al.
Publicado: (2021)

PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1
por: Liu, Lili, et al.
Publicado: (2017)

Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
por: Borneman, Rebecca M., et al.
Publicado: (2022)

PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model
por: Jin, Jiefu, et al.
Publicado: (2022)

DNA damage repair in ovarian cancer: unlocking the heterogeneity
por: Gee, Mary Ellen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f8hejpje79agak1ev8ka7ps707